AstraZeneca has become the latest drug firm to invest in Russian manufacturing capcity with the announcment of plans for a $150m facility in the country’s Kaluga region.
Late-stage cancer trials are the biggest challenge for pharmaceutical and biotech firms according to data presented at the Biotechnology Industry Organisation's (BIO) CEO and investor conference in Washington DC, US this week.
Passwords used to protect personal health information in Canadian clinical trials are often too easy to crack, according to a report in the Journal of Medical Internet Research (JMIR).
Takeda Pharmaceuticals has joined the growing list of pharma companies to forge strategic deals with contract research organisations (CRO) by signing new deals with Covance and Quintiles.
A global compulsory register of all contractors and subcontractors involved in each clinical trial should be created to increase transparency, according to a study.
Indian CRAMS firm Jubilant Life Sciences had an unhappy third quarter of fiscal 2011 with profits falling despite gains in generics and API manufacturing.
US-based Numira Biosciences has expanded its imaging and pre-clinical services portfolio after acquiring the efficacy pharmacology operating unit of Ricerca Biosciences.
QPS Holdings has acquired Taiwan’s Center of Toxicology and Preclinical Sciences (CTPS), continuing its expansion in the region’s rapidly expanding drug development sector.
Establishment of complex regulated preclinical studies in China is going to take a lot longer than expected, says CRL, with significant progress taking at least five years.
Albany Molecular Research Inc. (AMRI) has posted a fourth quarter loss for 2010 after charges relating to a non-cash goodwill and fixed asset impairment of $35.2m.
PPD and Charles River Laboratories (CRL) finished 2010 with very different quarters, each posting results that illustrate trends within the CRO sector.
The United States Pharmacopeoia (USP) will help regulators in sub-Saharan Africa ensure drug quality in a new scheme designed to boost testing and analysis capacity.
US Heparin maker Scientific Protein Laboratories (SPL) says it has resolved “many of the issues” addressed in the US Food and Drug Administration (FDA) warning letter it received late last month.
Ugandan drugmaker Quality Chemicals Industries (QCI) will invest $80m in manufacturing operations to boost capacity for the production of generic AIDS and malaria drugs.
Lab Research has signed a non-binding letter of intent (LOI) with a US private equity group interested in acquiring the preclinical contract research organisation (CRO).
The EU and US are using substandard medicines as an excuse to tighten IP rules, boosting pharma profits while making it harder for the poor to access drugs, according to Oxfam.
US CRO the Duke Clinical Research Institute (DCRI) has teamed up with Kaplan EduNeering to develop a training programme to meet rising global demand for qualified clinical researchers.
Supply chain strategy implementations are more likely to succeed when they have the active support of the board and senior executives, according to research.
Big pharma outsourcing will become much bolder in the next 12-18 months as companies attempt to “dramatically attack cost structures”, according to the Covance CEO.
Oystar has sold its Brazilian unit, Oystar Fabrima, to Sao Paulo-headquartered firm Masipack in an effort to focus its business on country’s the primary and secondary packaging markets.